Company Overview
Snapshot
Founded in June 2020 by Roi Ophir, Ariel Ben Dayan, Udi Bobrovsky, and Ohad Sharon, SpotitEarly operates with 11–50 employees. The company has raised $26.5M across three funding rounds from five investors, with Hanaco Ventures participating in multiple rounds. In January 2025, SpotitEarly secured a grant from the BIRD Foundation.
Business overview
SpotitEarly is a Health Tech & Life Sciences company developing a scent-based multi-cancer early detection screening test. The company combines a proprietary AI stack with bio-detectors to identify cancer in its early stages. Currently, SpotitEarly is conducting a large clinical trial for screening breast, lung, colon, and prostate cancers in a single test, serving the healthcare and life sciences markets.
Strategic signal
In March 2026, Fierce Healthcare recognized SpotitEarly as a “Fierce 15” Company of 2026. This acknowledgment highlights the company's innovative approach to cancer detection and its potential to significantly impact the healthcare industry, signaling strong market validation and future growth prospects to investors.
Log in to access full profile ›Company Intelligence Q&A
- What is SpotitEarly's core technology?
- SpotitEarly develops a scent-based multi-cancer early detection screening test that integrates a proprietary AI stack with bio-detectors to identify cancer at its nascent stages.
- Has SpotitEarly formed any strategic partnerships recently?
- In January 2026, Fox Chase Cancer Center announced a strategic partnership with SpotitEarly, bolstering the validity of its breakthrough early cancer detection technology.
- When was SpotitEarly founded and by whom?
- SpotitEarly was founded in June 2020 by Roi Ophir, Ariel Ben Dayan, Udi Bobrovsky, and Ohad Sharon.
- What recognition has SpotitEarly received?
- In March 2026, Fierce Healthcare named SpotitEarly a “Fierce 15” Company of 2026, recognizing its innovative contributions to the healthcare sector.